MENUNews Archive
Date: 11/18/2013
After 27 years leading the University of Michigan Rogel Cancer Center, founding director Max S. Wicha, M.D., has announced that he will step down as director. While serving as director, Wicha has continued to maintain his laboratory research and clinical practice seeing patients with breast cancer. In 2003, he was part of the team that first identified breast cancer stem cells.
Date: 11/08/2013
For low-risk women, the likelihood that they get tested for the infection that causes cervical cancer (human papillomavirus or HPV) may depend on what clinic they visit, their doctor's status and whether their provider is male or female, a University of Michigan Health System study shows.
Date: 10/31/2013
Researchers from the University of Michigan Rogel Cancer Center have identified new proteins that control the function of critical immune cell subsets called T-cells, which are responsible for a serious and often deadly side effect of lifesaving bone marrow transplants.
Date: 10/24/2013
Eric Fearon among 3 U-M faculty members in this year's class.
Date: 10/16/2013
Adrenal cancer researchers at the University of Michigan Rogel Cancer Center are seeing the results of their laboratory studies translate to a clinical trial to test a potential new therapy in patients.
Date: 10/08/2013
Ann Arbor-area residents have one last opportunity to join the movement to create a world with less cancer and more birthdays by participating in Cancer Prevention Study-3 (CPS-3), a historic study that has the potential to change the face of cancer for future generations.
Date: 10/07/2013
About a quarter of women experience moderate to severe pain for many years after their treatment ends. In many cases, it's a type of pain that is challenging to treat, with few or no effective options.
Date: 10/03/2013
A microfluidic chip developed at the University of Michigan is among the best at capturing elusive circulating tumor cells from blood -- and it can support the cells' growth for further analysis.
Date: 09/26/2013
Michigan Medicine has begun offering a new urine test called Mi-Prostate Score to improve on PSA screening for prostate cancer. The test incorporates three specific markers that could indicate cancer and studies have shown that the combination is far more accurate than PSA alone.